drugset / Trial / NCT07634744
A Phase IIa Study in Primary IgA Nephropathy Patients
NaSingle-groupOpen-labelTreatment
Summary
This is a phase IIa, multicenter, single-arm, open-label study to evaluate the safety and efficacy of XH-S003 in patients with primary IgA nephropathy
Timeline
- Start
- 2024-12-31
- Primary completion
- 2026-04-23
- Completion
- 2026-04-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XH-S003 | Unknown | 25 mg | Oral |
| Subject | XH-S003 | Unknown | 100 mg | Oral |